One of the essential organs of the human body is the liver, and it performs significant functions, such as the removal of harmful substances from the blood, maintains an adequate level of chemicals in the body, and stores nutrients for all cellular and biological activities. Improper functioning of the liver causes many severe diseases, such as hepatitis A, B, C, primary biliary cirrhosis, and tumors. Some inherited conditions, such as Wilson's disease, alagille syndrome, and hemochromatosis, are also occurred by improper functioning of the liver. Some of the primary reasons for the improper functioning of the liver are genetic disorder, excessive alcohol consumption, and obesity. Some of these may also lead to permanent damage to the liver. Common symptoms of liver disease include fatigue, nausea, sudden weight loss, swollen abdomen, and jaundice (yellow discoloration of the skin).
MARKET DYNAMICS
The liver medicine market has shown a significant evolution over the forecast period. A sedentary lifestyle drives the market, obesity, viral hepatitis, genetic disorders, unhealthy diet, and excessive alcohol consumption are some of the factors that are fueling the growth of liver disease prevalence in developing countries. Moreover, the rising prevalence of liver diseases globally is primarily driving the liver medicine market towards development. With the increasing prevalence of liver diseases, increasing awareness has become a necessity. Government and not-for-profit organizations play a crucial role in the rising awareness about liver diseases around the world. These organizations promote the awareness of the liver-related diseases and support for research and development for the prevention, treatment, and cure of liver diseases. However, stringent government regulations (FDA, MHRA), high cost incurred in drug research and development pose a crucial challenge for the liver disease treatment Industry. Side effect associated with medication is the growing concern expected for declining market value. Furthermore, new research and development will provide immense opportunities for market players. For instance, Yaqrit Limited has developed a new product, Yaq-001, which will be introduced in 3 years to treat chronic liver diseases.
MARKET SCOPE
The "Liver Medicine Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical in the healthcare industry, with a particular focus on the global market trend analysis. This report provides an outline of the liver medicine market with detailed market segmentation by treatment modality, disease type, and end-user. The liver medicine market is expected to witness high growth during the forecast period. The report focusses on the vital statistics on the market status of the leading players in the liver medicine market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The market is segmented based on treatment modality, disease type, and end-user. Based on treatment modality, the market is categorized as anti-viral, vaccines, chemotherapy, immunosuppressive agents, and corticosteroids. Based on disease type, segmentation of the market is into hepatitis, non- alcoholic fatty liver disease, alcohol-induced liver disease, and liver cancer. Based on end-user, segmentation of the market is into the hospitals, specialty clinics, and others.
REGIONAL FRAMEWORK
The report states a complete outline of the industry, including both quantitative and qualitative information. The report also gives a sketch and forecast of the liver medicine market based on various segments. It also comprises market size and forecast estimates from the year 2020 to2028with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South & Central America. The liver medicine market by each region is later subdivided into respective countries and segments. It consists of the analysis and forecast of 18 countries globally, along with the recent trend and opportunities prevailing in the region.
The report analyzes factors affecting the liver medicine market from both the demand and supply side. Moreover, it assesses market dynamics affecting the market during the forecast period, i.e., drivers, restraints, opportunities, and future trends.
The report also comprises a precise PEST analysis for all five regions, namely; North America, Europe, APAC, MEA, and South & Central America, after evaluating political, economic, social, and technological factors affecting the liver medicine market in these regions.
MARKET PLAYERS
The report contains critical developments in the liver medicine market as organic and inorganic growth strategies. Multiple firms are focusing on organic growth strategies like product approvals, product launches, and others, such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions and partnerships & collaborations. These activities have paved the way for the expansion of business and customer base of market players. The market players from the liver medicine market are anticipated to have profitable growth opportunities in the coming years with the rising demand for liver medicines in the global market. Given below is the list of few companies engaged in the liver medicine market.
The report also contains the profiles of key players in the liver medicine market, along with their SWOT analysis and market strategies. Additionally, the report focuses on leading market players with information on company profiles, components, and services provided, financial information of the last three years, critical development in the past five years.
- Gilead Sciences, Inc.
- Zydus Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited.
- Novartis AG
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Sanofi
- Abbott
- Bayer AG
- Johnson & Johnson Private Limited
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the current study.